News
Sotorasib in the Treatment of a Patient with NSCLC and DIC – A Case Report
Sotorasib is the first clinically used inhibitor of the KRAS oncogene with the G12C mutation. Its efficacy in the targeted treatment of non-small cell lung cancer (NSCLC) is still under research, but it is expected to bring significant benefits. The effect of sotorasib in a patient with a low baseline performance status (PS) and active brain metastases is presented in the following case report.
Incidence of Brain Metastases and Intracranial Activity of Sotorasib in Patients with NSCLC with G12C Mutation of the KRAS Oncogene
Sotorasib is the first targeted drug approved for the treatment of metastatic non-small cell lung…
“Customized Schizophrenia Treatment”: Benefits of Therapeutic Innovations in Inpatient and Outpatient Care Thanks to Gentler Antipsychotics
In the field of schizophrenia treatment, the possibility of significantly greater…
Angiodysplasia as a Serious Problem in Patients with von Willebrand Disease − Case Study
Bleeding into the gastrointestinal tract can become a very significant cause of morbidity and mortality...
Pharmacotherapy of Glaucoma in a Nutshell According to the Latest Recommendations of the European Glaucoma Society
The European Glaucoma Society published its latest, 5th version of recommendations for the treatment...
Model of Risk of Bleeding Associated with Physical Activity in Hemophiliacs with Factor and Non-Factor Treatment
In the treatment of hemophilia A, both FVIII concentrate replacement therapy and non-factor therapy…
When to Consider Gaucher Disease and How to Diagnose It Early and Correctly
Considering Gaucher disease (GD) as a cause of a patient's problems, especially in the case of…
COMMENTARY FROM PRACTICE: On Some Aspects of Care for Patients with Parkinson's Disease
What issues do we still encounter in the diagnosis and treatment of Parkinson's disease even today,...
Detection of ceftazidime/avibactam-resistant Enterobacteriaceae strains using a new rapid test
Ceftazidime/avibactam (CZA) is a relatively new antibiotic with very good efficacy against…
Diagnosing Myelodysplastic Syndrome According to MDS Europe
In 2021, the European Hematology Association (EHA) endorsed the recommendations of the MDS Europe…